CL2012002551A1 - Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. - Google Patents

Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.

Info

Publication number
CL2012002551A1
CL2012002551A1 CL2012002551A CL2012002551A CL2012002551A1 CL 2012002551 A1 CL2012002551 A1 CL 2012002551A1 CL 2012002551 A CL2012002551 A CL 2012002551A CL 2012002551 A CL2012002551 A CL 2012002551A CL 2012002551 A1 CL2012002551 A1 CL 2012002551A1
Authority
CL
Chile
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
CL2012002551A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Schiene
Funke Petra Bloms
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CL2012002551A1 publication Critical patent/CL2012002551A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012002551A 2010-06-15 2012-09-14 Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. CL2012002551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15

Publications (1)

Publication Number Publication Date
CL2012002551A1 true CL2012002551A1 (es) 2012-11-09

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002551A CL2012002551A1 (es) 2010-06-15 2012-09-14 Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.

Country Status (29)

Country Link
US (3) US8846765B2 (OSRAM)
EP (2) EP2992877A1 (OSRAM)
JP (3) JP6133772B2 (OSRAM)
KR (1) KR101831616B1 (OSRAM)
CN (1) CN103108631B (OSRAM)
AR (1) AR081931A1 (OSRAM)
AU (2) AU2011267474B2 (OSRAM)
BR (1) BR112012031836A2 (OSRAM)
CA (1) CA2796774C (OSRAM)
CL (1) CL2012002551A1 (OSRAM)
CO (1) CO6602157A2 (OSRAM)
CY (1) CY1117118T1 (OSRAM)
DK (1) DK2582366T3 (OSRAM)
EC (2) ECSP12012217A (OSRAM)
ES (1) ES2560676T3 (OSRAM)
HK (1) HK1215787A1 (OSRAM)
HR (1) HRP20151327T1 (OSRAM)
HU (1) HUE026619T2 (OSRAM)
IL (1) IL221926A (OSRAM)
MX (1) MX2012014482A (OSRAM)
NZ (1) NZ602625A (OSRAM)
PE (2) PE20130243A1 (OSRAM)
PL (1) PL2582366T3 (OSRAM)
PT (1) PT2582366E (OSRAM)
RS (1) RS54439B1 (OSRAM)
RU (2) RU2589692C2 (OSRAM)
SI (1) SI2582366T1 (OSRAM)
WO (1) WO2011157391A1 (OSRAM)
ZA (1) ZA201208646B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN104519878A (zh) * 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
RS59687B1 (sr) * 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
ES2755809T3 (es) 2013-03-15 2020-04-23 Janssen Pharmaceutica Nv Composición farmacéutica de hidrocloruro de S-ketamina
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
JP6545788B2 (ja) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
WO2016044150A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão
AU2019253028B2 (en) 2018-04-12 2024-05-30 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
CN114126595A (zh) 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US7700122B1 (en) * 1998-07-16 2010-04-20 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an NMDA antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
CN1691936A (zh) 2002-09-09 2005-11-02 恩多制药公司 立即释放和延长释放组合的镇痛药组合物
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
SI2012763T1 (sl) 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
AU2007256352A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
MX360289B (es) * 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
UY33618A (es) 2010-09-21 2012-03-30 Purdue Pharma Lp Analogos de buprenorfina
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
RS54711B1 (sr) 2011-03-04 2016-08-31 Grünenthal GmbH Parenteralno davanje tapentadola
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法

Also Published As

Publication number Publication date
US20170333369A1 (en) 2017-11-23
US10813890B2 (en) 2020-10-27
AR081931A1 (es) 2012-10-31
KR20130111945A (ko) 2013-10-11
ES2560676T3 (es) 2016-02-22
US20110306674A1 (en) 2011-12-15
RU2016119041A (ru) 2017-11-20
CA2796774A1 (en) 2011-12-22
HK1184370A1 (zh) 2014-01-24
AU2016219643A1 (en) 2016-09-15
PT2582366E (pt) 2016-01-26
CY1117118T1 (el) 2017-04-05
JP6423036B2 (ja) 2018-11-14
ECSP19047259A (es) 2019-07-31
AU2011267474A1 (en) 2013-01-10
PE20160531A1 (es) 2016-06-05
US8846765B2 (en) 2014-09-30
CO6602157A2 (es) 2013-01-18
CN103108631B (zh) 2015-08-26
RS54439B1 (sr) 2016-06-30
WO2011157391A1 (en) 2011-12-22
JP6197007B2 (ja) 2017-09-13
AU2016219643B2 (en) 2018-04-12
AU2011267474B2 (en) 2016-05-26
EP2582366A1 (en) 2013-04-24
HUE026619T2 (en) 2016-06-28
CA2796774C (en) 2020-06-02
HK1215787A1 (en) 2016-09-15
US20140309311A1 (en) 2014-10-16
RU2013101515A (ru) 2014-07-20
JP2013528629A (ja) 2013-07-11
RU2675261C2 (ru) 2018-12-18
NZ602625A (en) 2014-03-28
ZA201208646B (en) 2013-09-25
MX2012014482A (es) 2013-02-21
ECSP12012217A (es) 2012-11-30
CN103108631A (zh) 2013-05-15
DK2582366T3 (en) 2015-12-07
KR101831616B1 (ko) 2018-04-04
BR112012031836A2 (pt) 2016-11-08
JP2017141277A (ja) 2017-08-17
EP2582366B1 (en) 2015-10-28
PE20130243A1 (es) 2013-03-22
RU2589692C2 (ru) 2016-07-10
IL221926A (en) 2015-08-31
JP2015232015A (ja) 2015-12-24
JP6133772B2 (ja) 2017-05-24
EP2992877A1 (en) 2016-03-09
SI2582366T1 (sl) 2016-02-29
PL2582366T3 (pl) 2016-04-29
HRP20151327T1 (hr) 2016-01-01

Similar Documents

Publication Publication Date Title
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20150326A (es) Inhibidores de autotaxina
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
DOP2012000006A (es) Agonista de gpr119
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides